Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Krystal Biotech (KRYS)

Krystal Biotech Q4 revenue rises to $107.1 million; net income $51.4 million

Positive Impact 3 of 5 earnings Written later

Krystal Biotech reported fourth-quarter and full-year 2025 results, with product revenue from VYJUVEK rising from the prior-year periods. Net income for the quarter was $51.4 million, or $1.70 per diluted share, compared with $45.5 million, or $1.52 per diluted share, a year earlier. The company also issued fiscal 2026 non-GAAP R&D and SG&A expense guidance of $175.0 million to $195.0 million.

Key points

  • Q4 2025 product revenue, net, was $107.1 million, up from $91.1 million in Q4 2024.
  • Full-year 2025 product revenue, net, was $389.1 million, up from $290.5 million in 2024.
  • Full-year 2025 net income was $204.8 million, or $6.84 per diluted share, versus $89.2 million, or $3.00 per diluted share, in 2024.
  • FY 2026 non-GAAP R&D and SG&A expense guidance is $175.0 million to $195.0 million, excluding stock-based compensation.

The filing

CompanyKrystal Biotech (KRYS)
Form8-K, current report
Filed with the SECFeb 17, 2026, 7:06 AM ET
Accession number0001711279-26-000018

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 17, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.